Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • thondeboer
    Member
    • Jan 2009
    • 24

    Looking for Beta testers for Strand NGS module

    Hi,

    We at Strand Life Sciences are currently working on an application for the analysis of ChIP-SEQ, RNA-SEQ and DNA Variation data and we are looking for BETA TESTERS!

    The application starts with pre-aligned NGS data (in SAM/BAM format) and is built on the same platform as Agilent GeneSpring (and can be fully integrated with GeneSpring) and allows for the following analysis

    ChIP-SEQ
    1. Import of SAM/BAM file of aligned data
    2. The detection of peaks in the coverage by two algorithms
    3. PICS
    4. MACS
  • Motif detection using the GADEM algorithm
  • Detection of up- and downstream genes
  • GO and Pathway analysis of the affected genes


  • RNA-SEQ
    The RNA-SEQ experiment type allows for the measurement of expression levels of known transcripts and the detection of novel genes. It supports alternative splicing analysis as well as statistical analysis of differentially expressed genes.

    DNA Variant analysis
    The DNA Variant analysis experiment type allows for the detection of SNPs, MNPs, large and small InDels and large structural variants, such as translocations and inversions etc. Annotation of the found variants with previously published variants from dbSNPs as well as the analysis of the effect of the variants on the coding regions of the genes, such as frameshifts, insertions/deletions, etc.

    Let me know if you are interested in BETA testing and once we release this product, we give you 6 months free access!

    Sincerely yours,

    Thon de Boer
    Dir. of Product Manager
    Strand Life Sciences
Thon
__________________________________
Thon de Boer, Ph.D.
Director of Product Management, Software
Strand Life Sciences
548 Market Street, Suite 82804
San Francisco, CA 94104, USA
[email protected]
www.strandls.com
Pioneers in Discovery Research Informatics
_______________________________________
  • Lee Sam
    Member
    • Oct 2008
    • 57

    #2
    How many samples can you support in a cohort? Tens, hundreds? That's traditionally been the issue when we try and use integrated tools.

    Comment

    • thondeboer
      Member
      • Jan 2009
      • 24

      #3
      We are aiming and designed it for being able to do hundreds, but frankly have not found these kinds of data sets but simulations are in the works...What kind of data sets do you have access to? Hundreds of what kind of coverage and is it whole genome or targeted?
      Thon
      __________________________________
      Thon de Boer, Ph.D.
      Director of Product Management, Software
      Strand Life Sciences
      548 Market Street, Suite 82804
      San Francisco, CA 94104, USA
      [email protected]
      www.strandls.com
      Pioneers in Discovery Research Informatics
      _______________________________________

      Comment

      • NextGenSeq
        Senior Member
        • Apr 2009
        • 482

        #4
        How do we sign up? What type of hardware and operating system is needed?

        Comment

        • thondeboer
          Member
          • Jan 2009
          • 24

          #5
          Just let me know you are interested and send me a private message with your email address and I will send you the info once we are ready to start the beta (in about a week or so).

          The NGS Module is a desktop application at the moment (we are working on a cloud version as well) and will run on Windows, Linux and Mac OSX at although it can run in 2 GB, we recommend 64bit machines with at least 4 GB of memory....
          Thon
          __________________________________
          Thon de Boer, Ph.D.
          Director of Product Management, Software
          Strand Life Sciences
          548 Market Street, Suite 82804
          San Francisco, CA 94104, USA
          [email protected]
          www.strandls.com
          Pioneers in Discovery Research Informatics
          _______________________________________

          Comment

          • thondeboer
            Member
            • Jan 2009
            • 24

            #6
            We have finally started the beta program for Avadis NGS by Strand.
            If you are interested to participate, please send me a private message here and I will add you to the list....
            Thon
            __________________________________
            Thon de Boer, Ph.D.
            Director of Product Management, Software
            Strand Life Sciences
            548 Market Street, Suite 82804
            San Francisco, CA 94104, USA
            [email protected]
            www.strandls.com
            Pioneers in Discovery Research Informatics
            _______________________________________

            Comment

            • dawe
              Senior Member
              • Apr 2009
              • 258

              #7
              Originally posted by thondeboer View Post
              Hi,

              We at Strand Life Sciences are currently working on an application for the analysis of ChIP-SEQ, RNA-SEQ and DNA Variation data and we are looking for BETA TESTERS!

              The application starts with pre-aligned NGS data (in SAM/BAM format) and is built on the same platform as Agilent GeneSpring (and can be fully integrated with GeneSpring) and allows for the following analysis
              We had a really bad experience with GeneSpring GX and its development road. Does this suite need an Oracle DB backend?

              d

              Comment

              • mgundry
                Junior Member
                • Jan 2010
                • 1

                #8
                id like to test it out. let me know what i need to do.

                Comment

                • aunderwo
                  Junior Member
                  • Jan 2009
                  • 6

                  #9
                  I'd be happy to test

                  I am a bioinfomatician but have many users who would like to try software with an intuitive UI. Tried to pm you but this seemed to be disabled.

                  Please get in touch if looking for a beta tester

                  Anthony

                  Comment

                  • Latest Articles

                    Collapse

                    • SEQadmin2
                      Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
                      by SEQadmin2


                      Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

                      The systematic characterization of the human proteome has
                      ...
                      07-20-2026, 11:48 AM
                    • SEQadmin2
                      Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
                      by SEQadmin2



                      Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
                      ...
                      07-09-2026, 11:10 AM
                    • SEQadmin2
                      Cancer Drug Resistance: The Lingering Barrier to Rising Survival
                      by SEQadmin2



                      Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

                      There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
                      07-08-2026, 05:17 AM

                    ad_right_rmr

                    Collapse

                    News

                    Collapse

                    Topics Statistics Last Post
                    Started by SEQadmin2, 07-24-2026, 12:17 PM
                    0 responses
                    20 views
                    0 reactions
                    Last Post SEQadmin2  
                    Started by SEQadmin2, 07-23-2026, 11:41 AM
                    0 responses
                    19 views
                    0 reactions
                    Last Post SEQadmin2  
                    Started by SEQadmin2, 07-20-2026, 11:10 AM
                    0 responses
                    25 views
                    0 reactions
                    Last Post SEQadmin2  
                    Started by SEQadmin2, 07-13-2026, 10:26 AM
                    0 responses
                    38 views
                    0 reactions
                    Last Post SEQadmin2  
                    Working...